

U.S. Physician & Payer Forum

*Crucial Market Insight from
Physicians and Payers*



2010 Titles



Emerging Biologics and Novel Oral Agents in RA: How Will New Agents Secure Market Share and Payer Acceptance in a Crowded Market?

Hepatitis C: Reimbursement and Uptake of Novel Antivirals Among Payers and Prescribers

Clinician and Payer Attitudes to Novel Therapies for Neuropathic Pain: How Much Will Cost and other Differentiating Features Influence Use of New Therapies?

Hospital Infections: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals From P&T Committee Members, Infectious Disease Specialists, and Internists.

How Will Clinician and Payer Attitudes to Mutation-Specific Prescribing Shape the NSCLC and CRC Markets?

Lorcaserin, Contrave and Qnexa; How Will Physician and Payer Attitudes Shape the Market for These Emerging Obesity Therapies?

Physician and Payer Acceptance of Emerging Fixed-Dose Combination Inhalers for Asthma and COPD.

Stelara and Briakinumab in Psoriasis: Do Payers and Dermatologists Foresee a Dramatic Shift in Psoriasis Treatment and Drug Coverage?

The Expanding Biologics Landscape in CD and UC: Clinician and Payer Perspective on the Role of Premium-Priced Biologics in UC and CD Treatment.

Pulmonary Arterial Hypertension: How Will Physicians and Payers Shape an Evolving Market

Physician and Payer Attitudes Towards Effient, Brilinta and Other Novel Oral Antiplatelets for ACS and CHD

Biologics and Formulations for Nociceptive Pain: Will these agents gain widespread physician and payer acceptance despite a crowded market?



A Decision Resources, Inc. Company

www.DecisionResources.com

© 2010 Decision Resources, Inc.